CommentPatisiran in hereditary transthyretin-mediated amyloidosis
References (10)
Cell and molecular biology of transthyretin and thyroid hormones
Int Rev Cytol
(2007)- et al.
Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care
Ther Clin Risk Manag
(2020) - et al.
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
J Neurol
(2013) - et al.
Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
N Engl J Med
(2018) - et al.
Inotersen treatment for patients with hereditary transthyretin amyloidosis
N Engl J Med
(2018)
There are more references available in the full text version of this article.
Cited by (8)
Protein-based delivery systems for RNA delivery
2023, Journal of Controlled ReleaseNovel vectors and approaches for gene therapy in liver diseases
2021, JHEP ReportsCitation Excerpt :This LNP is coated by the host apolipoprotein E (ApoE) that triggers its transport into hepatocytes via low-density lipoprotein receptor (LDLR)-mediated endocytosis. The treatment suppresses the deposition of amyloid fibrils and was approved as the first siRNA drug (patisiran) by the FDA in 2018 for the treatment of TTR-type familial amyloid polyneuropathy.61 A similar strategy is under clinical development for the treatment of elevated LDL-cholesterol and hypercholesterolemia using siRNA-LNPs targeting PCSK9 and ApoB, respectively.62
Development of Cationic Lipid LAH4-L1 siRNA Complexes for Focused Ultrasound Enhanced Tumor Uptake
2023, Molecular PharmaceuticsPatisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy
2023, Heart International
© 2020 Elsevier Ltd. All rights reserved.